NCT02091999 (Clinical Trial/ ASG-22CE)

Study Title
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4. (NCT02091999)

Trial Description
The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE  (formerly AGS-22M6E); AGS-22CE, AGS-22M, AGS-22ME, ASG-22ME, unconjugated : AGS-22C3 or AGSM6) as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors. This trial is sponsored by Agensys, Inc. [1]

Study Data

  • Condition: Metastatic Urothelial Cancer and Other Malignant Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • ASG-22CE
  • Phase: I
  • Estimated Enrollment: 200
  • Start: June 2014
  • Estimated Completion: December 2018
  • Last verified: July 2017

Study Schematic

NCT02091999

Click here to Return to Drug map

Last Editorial review: August 25, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.